Cancer Dx test maker Veracyte launches successful IPO

A month after filing IPO plans, molecular diagnostics test maker Veracyte ($VCYT) finally went public on Oct. 30. The South San Francisco company said it sold 5 million shares of common stock for $13 each and pulled in $65 million. That came in at the low end of Veracyte's range. The company initially said it would offer 4.7 million shares priced between $13 and $15 each. Veracyte, a 2013 Fierce 15 winner, also granted the underwriters a 30-day option to snatch up an additional 750,000 shares of common stock at the initial public offering price to cover any overallotments. Veracyte's Afirma test combines a specialized cytopathology assessment and gene-expression test to determine whether a thyroid nodule is benign or cancerous. Story

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.